Angiogenesis inhibitor improves brain tumor survival by reducing edema

March 30, 2009

Mice treated with experimental drug cediranib live longer despite continued tumor growth

The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (MGH) researchers. Their report, to be published in the Journal of Clinical Oncology and receiving early online release, describes how treatment with the experimental drug cediranib reduced edema and improved survival in three mouse models of glioblastoma.

"Our findings suggest that antiangiogenesis therapy can increase patient survival even in the face of persistent tumor growth," says Rakesh K. Jain, PhD, director of the Steele Laboratory in the MGH Department of Radiation Oncology, the study's co-senior author. "In glioblastoma clinical trials, it is important to separate survival analysis from that of tumor response to therapy, since many factors combine to cause patient deaths."

Cediranib inhibits the potent angiogenesis factor VEGF, which is known to be abundantly present in glioblastomas and play a critical role in tumor blood vessel formation. A 2007 report from an ongoing clinical trial at the MGH Cancer Center found that the drug temporarily normalized abnormal, leaky blood vessels in glioblastomas that had recurred after surgery, radiation or chemotherapy - reducing edema and apparently the size of the tumors. But the exact mechanism underlying the effects was unclear, since the imaging technology used to track tumor progression could not distinguish between effects on blood vessels and an actual reduction in tumor size.

"We frequently see beneficial effects from drugs in patients without fully understanding the mechanism of action," says A. Gregory Sorensen, MD, of the MGH Radiology Department and Martinos Center for Biomedical Imaging, co-senior author of the report.. "The fact that anti-VEGF agents seem to provide clear benefits in some glioblastoma patients adds to the urgency of understanding the mechanisms that underlie these clinical improvements. We need to learn how to tailor our treatments to benefit even more patients."

The current study was designed to clarify whether cediranib's clinical effects primarily resulted from reduction of edema, which has significant consequences within the brain, or from a direct anti-tumor effect. The researchers implanted fluorescently labeled human or rat glioblastoma cells into the brains of mice and directly observed the tumors and surrounding tissue through transparent windows through the skull. Once tumors began growing, some of the mice received daily doses of cediranib, along with daily measurement of tumor growth, edema and of blood vessel structure and function.

Mice treated with cediranib were found to have significant reductions in the size and permeability of tumor-associated blood vessels, compared with animals that did not receive the drug. Although treatment did not reduce the rate of tumor growth, mice receiving cediranib lived significantly longer than the control animals. Another group of tumor-bearing mice received the steroid drug most commonly used to treat edema, and though those animals also lived longer than controls, the survival benefit was greater for the mice receiving cediranib.

"This is the first paper to show that vascular normalization alone, without chemotherapy, can be effective against some tumors by controlling edema and that this anti-edema effect is better than that of currently used steroids," Jain says. "Unfortunately, these anti-VEGF agents did not slow the tumor growth rate in these models; and since recurrent glioblastomas are highly resistant to currently used chemotherapy drugs, even if vascular normalization increases drug delivery, there may be little or no additional increase in patient survival. We urgently need to find better anti-tumor and anti-angiogenic agents."

Jain also notes that it will be important to identify biomarkers that may indicate which patients are most likely to benefit from treatment with angiogenesis inhibitors and to identify the mechanisms by which glioblastomas and other tumors resist anti-VEGF therapies. Jain is the Cook Professor of Tumor Biology and Sorensen is an associate professor of Radiology at Harvard Medical School.

Massachusetts General Hospital

---

---

	New treatments for chronic edema in women? (Postgraduate Medicine) by JTE Multimedia Are there any new therapeutic methods for chronic edema in women? Original Publication Date: August 2008
	Edema of the Lung (American Lectures in Living Chemistry) by John S. Prichard (Author)
	Macular Edema: A Practical Approach (Developments in Ophthalmology) by G. Coscas (Author) For many years, diagnosing macular edema at an early stage has been a main difficulty. Recently, multiple and remarkable advances of modern imaging technologies which allow recognition of the main etiologies, have immensely improved its diagnosis and treatment. In this volume, different patterns and etiologies of macular edema are described and the importance of preserving the photoreceptors at an early stage in order to retain center visual acuity is discussed. It brings together the most recent data and evidence-based medicine, and, on the other hand, the pathophysiological basis of macular edema and the different approaches for drug delivery to the posterior segment are presented. Recommendations for treatment procedures or different therapies have been carefully analyzed and...
	Brain Edema XIV (Acta Neurochirurgica Supplementum) by Zbigniew Czernicki (Editor), Alexander Baethmann (Editor), Umeo Ito (Editor), Yoichi Katayama (Editor), Toshihiko Kuroiwa (Editor), Alexander David Mendelow (Editor) The nearly 100 papers written by internationally recognized experts cover the broad spectrum of brain edema and tissue injury problems. The main topics treated are: ischemia and the blood-brain barrier disorders – hydrocephalus - subarachnoid hemorrhage and intracerebral hemorrhage - imaging and diagnosis - trauma and brain tissue injury - tumor - treatment – nanoparticles and brain edema.
	Brain Edema XIII (Acta Neurochirurgica Supplementum) by Julian T. Hoff (Editor), Richard F. Keep (Editor), Guohua Xi (Editor), Ya Hua (Editor) This volume contains 93 papers from internationally recognized experts in the field of brain edema and brain injury. The papers include human and animal studies on edema following stroke, cerebral hemorrhage, traumatic brain injury, spinal cord injury and hydrocephalus. Papers also address fluid dynamics in the brain (including the role of aquaporins).
	Recent Progress in the Study and Therapy of Brain Edema by K. Go (Editor)
	Edema: Webster's Timeline History, 1778 - 2001 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Edema," including when used in literature (e.g. all authors that might have Edema in their name). As such, this book represents the largest compilation of timeline events associated with Edema when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences (linguistics,...
	Edema: Webster's Timeline History, 2002 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Edema," including when used in literature (e.g. all authors that might have Edema in their name). As such, this book represents the largest compilation of timeline events associated with Edema when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences (linguistics,...
	Pulmonary Edema in Man and Animals by Aldo A., M.d. Luisada (Author)
	Brain edema: Pathology, diagnosis, and therapy (Advances in neurology) by J. Cervos-Navaro (Author), R. Ferszt (Author)